Clinical Efficacy of Modified Simiao Yongan Decoction and Endovascular Therapy for Diabetic Foot Ulcers

Inclusion Criteria: * Diagnosed with a Diabetic Foot Ulcer (DFU). * Assessed as Rutherford classification 4-5 or Wagner classification 2-4. * Successfully received lower extremity endovascular intervention. * Meets the Traditional Chinese Medicine diagnostic criteria for "Damp-Heat Toxins Accumulation Syndrome". Patients must exhibit at least two primary symptoms (red/swollen/hot/painful limb, high exudate or purulent secretion with foul odor, dark purple wound/necrotic tissue, elevated local skin temperature) and at least one secondary symptom (dry mouth/bitter taste, dry stool, red tongue with yellow greasy coating, rapid/string-taut pulse). Exclusion Criteria: * Patients with severe, uncontrolled life-threatening systemic diseases, such as severe heart failure (NYHA class III-IV), severe hepatic or renal dysfunction, or active malignancy. * Patients with active systemic sepsis, extensive gangrene, or severe osteomyelitis requiring immediate major amputation of the target limb. * Patients with known allergies, hypersensitivity, or severe adverse reactions to any of the herbal components of the Modified Simiao Yongan Decoction. * Patients with severe gastrointestinal disorders that would significantly impair the absorption of oral medications. * Women who are pregnant, planning to become pregnant, or currently lactating. * Patients with severe cognitive impairment, psychiatric disorders, or poor compliance that would prevent them from providing informed consent or adhering to the 24-month follow-up schedule. * Patients currently participating in, or who have participated in within the last 30 days, another interventional clinical trial.